- OS Therapies (OSTX, Financial) has acquired Advaxis Immunotherapies' listeria-based cancer immunotherapy assets from Ayala Pharmaceuticals.
- The acquisition includes three clinical-stage and eight pre-clinical candidates targeting over 30 cancer types.
- OS Therapies aims for approval of its lead asset, OST-HER2, by the end of 2025.
OS Therapies (OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, has successfully completed the acquisition of listeria-based cancer immunotherapy assets from Advaxis Immunotherapies, previously owned by Ayala Pharmaceuticals. This strategic acquisition positions OS Therapies as a global leader in this cutting-edge segment of cancer treatment.
The acquisition encompasses three clinical-stage cancer immunotherapy candidates: OST-AXAL for HPV-associated cancers, OST-503 for Non-Small Cell Lung Cancer (NSCLC) and Glioblastoma, as well as OST-PSA for Prostate Cancer. Additionally, OS Therapies has acquired eight pre-clinical candidates, broadening its pipeline by targeting over 30 different cancer types.
The company's lead candidate, OST-HER2, is set to prevent recurrence in fully-resected, lung metastatic osteosarcoma. It is anticipated to receive approval from relevant authorities by the end of 2025. This candidate has already demonstrated positive results in a Phase 2b clinical trial, enhancing its prospects for market success.
OS Therapies has also reinforced its intellectual property rights, which extend protection for its listeria-based immunotherapy platform until 2040. The global cancer immunotherapy market, valued at $126 billion in 2023, is projected to surpass $296 billion by 2033, underscoring the significant commercial potential of these assets.
